In HR-MDS and AML, time to look closer at the dual impact of TIM-3

TIM-3 is expressed on immune cells and myeloid cells, so targeting it provides potential to activate immune response and suppress leukemic cell proliferation.1,2

HR-MDS and AML patient prognosis

Why do patients face such a difficult prognosis?


Activate immune response and suppress leukemic cell proliferation

Can the TIM-3 pathway offer potential for dual impact?


AML, acute myeloid leukemia; HR-MDS, high-risk myelodysplastic syndrome; TIM-3, T cell immunoglobulin and mucin domain-3.

References: 1. Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341-352. 2. Sakuishi K, Ngiow SF, Sullivan JM, et al. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849.

This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.

 

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2020 Novartis AG. All rights reserved.

11/20 G-PIP-1238424